New AI-Powered 'Eye' could slash repeat breast cancer surgeries

NCT ID NCT07111728

Recruiting now Diagnosis Sponsor: Istituti Clinici Scientifici Maugeri SpA Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new handheld device that uses light and artificial intelligence to check for leftover cancer cells right after a breast lump is removed. The goal is to help surgeons remove all cancer in one go, avoiding a second surgery. About 104 women having breast-conserving surgery will take part, and the device's results will be compared to standard lab tests.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Spectra-BREAST system (hyperspectral imaging and Raman spectroscopy device)
What this could lead to: If successful, this device could help surgeons remove all cancer in one surgery, reducing the need for a second operation.
What could go wrong: This is an early-stage study with only 104 participants. The device may not be accurate enough in real-world use, and results may not apply to all breast cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm ductal breast carcinoma in situ invasive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Istituti Clinici Scientifici Maugeri IRCCS
RECRUITING

Pavia, Lombardy, 27100, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.